DK1506190T3 - (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker - Google Patents

(Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker

Info

Publication number
DK1506190T3
DK1506190T3 DK03752750T DK03752750T DK1506190T3 DK 1506190 T3 DK1506190 T3 DK 1506190T3 DK 03752750 T DK03752750 T DK 03752750T DK 03752750 T DK03752750 T DK 03752750T DK 1506190 T3 DK1506190 T3 DK 1506190T3
Authority
DK
Denmark
Prior art keywords
pyridazine
imidazol
methyl
nmda receptor
receptor blocker
Prior art date
Application number
DK03752750T
Other languages
English (en)
Inventor
Neidhart Marie-Paule Heitz
Bernd Buettelmann
Georg Jaeschke
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1506190T3 publication Critical patent/DK1506190T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03752750T 2002-05-16 2003-05-16 (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker DK1506190T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16

Publications (1)

Publication Number Publication Date
DK1506190T3 true DK1506190T3 (da) 2006-10-16

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03752750T DK1506190T3 (da) 2002-05-16 2003-05-16 (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker

Country Status (31)

Country Link
US (1) US7005432B2 (da)
EP (1) EP1506190B1 (da)
JP (1) JP4267569B2 (da)
KR (1) KR100632868B1 (da)
CN (1) CN1312151C (da)
AR (1) AR040010A1 (da)
AT (1) ATE329912T1 (da)
AU (1) AU2003242542B2 (da)
BR (1) BR0311177A (da)
CA (1) CA2485926C (da)
CL (1) CL2004001251A1 (da)
CY (1) CY1105159T1 (da)
DE (1) DE60306152T2 (da)
DK (1) DK1506190T3 (da)
ES (1) ES2265581T3 (da)
HK (1) HK1080845A1 (da)
HR (1) HRP20041060B1 (da)
IL (1) IL164922A (da)
MA (1) MA27117A1 (da)
ME (1) MEP76708A (da)
MX (1) MXPA04011253A (da)
NO (1) NO329605B1 (da)
NZ (1) NZ536310A (da)
PL (1) PL211340B1 (da)
PT (1) PT1506190E (da)
RS (1) RS51200B (da)
RU (1) RU2317294C2 (da)
SI (1) SI1506190T1 (da)
TN (1) TNSN04224A1 (da)
WO (1) WO2003097637A1 (da)
ZA (1) ZA200408789B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
JP5242380B2 (ja) * 2005-05-03 2013-07-24 メルク パテント ゲーエムベーハー 有機エレクトロルミネッセンス素子
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
SI2393360T1 (sl) 2009-02-05 2016-02-29 Takeda Pharmaceutical Company Limited Piridazinonske spojine
WO2012018058A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
DK3180329T3 (da) * 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
US10874104B2 (en) 2016-02-18 2020-12-29 Syngenta Participations Ag Pesticidally active pryazole derivatives
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
LT3830092T (lt) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801774T2 (xx) * 1996-03-08 1998-12-21 F.Hoffmann-La Roche Ag 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
PT1070708E (pt) * 1999-07-21 2004-05-31 Hoffmann La Roche Derivados de triazol
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
ES2225553T3 (es) * 2000-04-20 2005-03-16 F. Hoffmann-La Roche Ag Derivados de pirrolidina y piperidina y su empleo para el tratamiento de trastornos neurodegenerativos.
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2001296994A1 (en) 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
SI1506190T1 (sl) 2006-10-31
CN1653062A (zh) 2005-08-10
DE60306152D1 (de) 2006-07-27
JP2005532326A (ja) 2005-10-27
CN1312151C (zh) 2007-04-25
KR100632868B1 (ko) 2006-10-13
AU2003242542B2 (en) 2008-10-16
US7005432B2 (en) 2006-02-28
EP1506190A1 (en) 2005-02-16
MXPA04011253A (es) 2005-01-25
PL374224A1 (en) 2005-10-03
CA2485926C (en) 2009-11-24
ES2265581T3 (es) 2007-02-16
RS51200B (sr) 2010-12-31
RU2004136979A (ru) 2005-07-10
ZA200408789B (en) 2005-12-28
JP4267569B2 (ja) 2009-05-27
CY1105159T1 (el) 2009-11-04
CL2004001251A1 (es) 2005-04-22
DE60306152T2 (de) 2007-04-26
KR20040106558A (ko) 2004-12-17
MA27117A1 (fr) 2004-12-20
US20030229096A1 (en) 2003-12-11
BR0311177A (pt) 2005-03-15
MEP76708A (en) 2011-12-20
NO329605B1 (no) 2010-11-22
TNSN04224A1 (fr) 2007-03-12
WO2003097637A1 (en) 2003-11-27
ATE329912T1 (de) 2006-07-15
HRP20041060B1 (en) 2012-11-30
IL164922A (en) 2012-01-31
PT1506190E (pt) 2006-11-30
HK1080845A1 (en) 2006-05-04
NO20044666L (no) 2004-12-15
NZ536310A (en) 2007-08-31
RS98504A (en) 2006-12-15
AR040010A1 (es) 2005-03-09
HRP20041060A2 (en) 2005-06-30
EP1506190B1 (en) 2006-06-14
CA2485926A1 (en) 2003-11-27
PL211340B1 (pl) 2012-05-31
IL164922A0 (en) 2005-12-18
RU2317294C2 (ru) 2008-02-20
AU2003242542A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
DK1506190T3 (da) (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
DK1663996T3 (da) (Thio)carbamoylcyclohexanderivater som D3/D2-receptorantagonister
AU2003257094A1 (en) Substituted benzimidazole compounds
DE60328925D1 (de) Jittergenerator
EP1832069B8 (en) Voip network infrastructure components
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
ZA200409339B (en) Novel benzimidazole derivatives.
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DK1802307T3 (da) Pyrrolidinderivater som histamin-receptor-ligander
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
AU2003902860A0 (en) Benzimidazole compounds
AU2003257032A1 (en) Antibodies against c3a receptor
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
DK1636221T3 (da) 3-Heterocyclyl-azetidin-forbindelser, som er nytte som NK1/NK2 receptorantagonister
NO20042198L (no) Tetrahydrokarbazolderivater som ligander for G-proteinkoplede reseptorer (GPCR).
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
DK1560828T3 (da) Imidazoquinolinderivater som adenosin-A3-receptorligander
IL182314A0 (en) 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives